Plain-English translation of NCT06218199 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing two different approaches to treating early warning signs of worsening heart failure in people who have a Boston Scientific pacemaker or defibrillator with a HeartLogic sensor. When your device detects that your heart failure may be getting worse—even before you feel symptoms—doctors will randomly assign you to one of two standard treatments: either water pills (diuretics) or blood pressure-lowering medications (afterload reduction). The study will track whether one approach works better than the other at bringing your heart back to normal.
Right now, doctors aren't sure which medication works best when a heart device sends an early warning that heart failure is getting worse but you don't have symptoms yet. This study will help answer that question so future patients get the most effective treatment as soon as possible.
You likely qualify if…
You likely don't qualify if…
If your HeartLogic device sends an alert and you don't have symptoms, you'll be randomly assigned to either start or increase a water pill or a blood pressure-lowering medication. You'll have your heart device checked again about a week later to see if the medication is working. The study team will monitor your device remotely and follow up with you to see how you're doing, whether your symptoms develop, and whether you need additional treatment.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
United States